Updated data from a Phase 1/2 clinical trial, GARNET, evaluating GlaxoSmithKline’s (NYSE:GSK)
PD-1 inhibitor dostarlimab (acquired via the Tesaro merger) in women
with recurrent/advanced mismatch repair-deficient endometrial cancer who
progressed on or after platinum-based chemo, showed a treatment
benefit. The data were presented at the Society of Gynecologic Oncology
virtual congress.
In patients with measurable disease at baseline
with at least six months of follow-up at date cutoff (n=71), the overall
response rate was 42% (n=30/71), including nine complete responders.
Median duration of response had not been reached.
On the safety front, the most common
treatment-related adverse events were asthenia (weakness, lack of
energy)(15%), diarrhea (15%), fatigue (14%) and nausea (13%).
In March 2019, the company reported an ORR of 30% in patients with microsatellite instability-high endometrial cancer.
https://seekingalpha.com/news/3564076-glaxo-pdminus-1-inhibitor-shows-positive-action-in-endometrial-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.